Shareholders approve Merck and Schering-Plough deal
스크롤 이동 상태바
Shareholders approve Merck and Schering-Plough deal
기자명
메디칼라이터팀
입력 2009.08.11 00:00
수정 2009.08.11 08:31
댓글 0
The shareholders of both companies have both overwhelmingly backed Merck & Co."s acquisition of Schering-Plough Corp., a deal that allows Merck, the world"s eighth-biggest drugmaker by prescription medicine sales, to jump to second just behind Pfizer. Merck has its asthma and allergy treatment Singulair [montelukast] and cervical cancer vaccine Gardasil while Schering-Plough can contribute its allergy spray Nasonex [mometasone furoate monohydrate] and well known consumer products like Dr Scholl"s foot care.